naltrexone has been researched along with oxycodone in 64 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (1.56) | 18.7374 |
1990's | 2 (3.13) | 18.2507 |
2000's | 16 (25.00) | 29.6817 |
2010's | 32 (50.00) | 24.3611 |
2020's | 13 (20.31) | 2.80 |
Authors | Studies |
---|---|
Bousquet, AR; Howes, JF; Kotick, MP; Leland, DL; Polazzi, JO | 1 |
Strassburg, CP; Tukey, RH | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brockmöller, J; Friesacher, HR; Meyer, MJ; Neumann, VE; Tzvetkov, MV; Zdrazil, B | 1 |
Manfredi, B; Mantegazza, P; Panerai, AE; Sacerdote, P | 1 |
Borsodi, A; Hosztafi, S; Nevin, ST; Rónai, AZ; Spetea, M; Tóth, G | 1 |
Eissenberg, T; Harkins, SW; Riggins, EC; Weaver, MF | 1 |
Porter, SJ; Somogyi, AA; White, JM | 1 |
Burns, LH; Butera, PG; Chindalore, VL; Craven, RA; Friedmann, N; Yu, KP | 1 |
Burns, LH; Olmstead, MC | 1 |
Burns, LH; Leri, F | 1 |
Kamei, J; Nozaki, C; Saitoh, A; Tamura, N | 1 |
Kamei, J; Nozaki, C; Saitoh, A | 1 |
Burns, LH; Butera, PG; Friedmann, N; Moran, LV; Webster, LR; Wu, N | 1 |
Kamei, J; Nozaki, C | 1 |
Edwards, SR; Nielsen, CK; Smith, MT | 1 |
Webster, LR | 1 |
Burns, LH; Guo, W; Largent-Milnes, TM; Vanderah, TW; Wang, HY | 1 |
Fishman, M | 1 |
Lavine, G | 1 |
Kapoor, S | 1 |
Bigelow, GE; Harrison, JA; Lanier, RK; Strain, EC; Tompkins, DA | 1 |
Pergolizzi, JV; Raffa, RB | 1 |
Leppert, W | 1 |
Esfandyari, M; Heydari, A; Taheri, S; Tavakol, H | 1 |
Bass, A; Leibowitz, M; Pixton, GC; Rolleri, R; Sommerville, KW; Stark, JG; Zamora, CA | 1 |
Pappagallo, M; Sokolowska, M | 1 |
Müller-Lissner, S | 1 |
Pergolizzi, JV; Raffa, RB; Taylor, R | 1 |
Bramson, C; Malhotra, BK; Matschke, K; Salageanu, J; Wang, Q | 1 |
Bass, A; Bramson, C; Hale, ME; Malhotra, BK; Meisner, P; Pixton, G; Rauck, RL; Setnik, B; Sommerville, KW; Wilson, JG; Wolfram, G | 1 |
Bass, A; Bramson, C; Geoffroy, P; Levy-Cooperman, N; Malhotra, B; Matschke, K; Setnik, B; Sommerville, KW; Wolfram, G | 1 |
Dolgin, E | 1 |
Dahmke, H; Kullak-Ublick, GA; Kupferschmidt, H; Weiler, S | 1 |
Bramson, C; Gandelman, K; Lamson, M; Malhotra, B; Matschke, K; Salageanu, J | 1 |
Backonja, M; Bass, A; Malhotra, BK; Matschke, K; Setnik, B; Sommerville, KW; Webster, LR; Wolfram, G | 1 |
Davis, MP | 1 |
Factor, JA; Panlilio, LV; Schindler, CW; Secci, ME | 1 |
Bradberry, CW; Panlilio, LV; Schindler, CW; Secci, ME | 1 |
Barsdorf, AI; Bass, A; Masters, ET; Pixton, G; Weil, AJ; Wilson, JG; Wolfram, G | 1 |
Adhikary, S; Bossert, JM; Fredriksson, I; Hoots, JK; Shaham, Y; Venniro, M; Zhang, M | 1 |
Candy, B; Jones, L; Larkin, PJ; Stone, P; Vickerstaff, V | 2 |
Blackney, KA; Edwards, DA; Kamdar, NV; Liu, CA | 1 |
Kokki, H; Kokki, M; Kuronen, M; Nyyssönen, T; Savolainen, S | 1 |
An, J; Chen, C; Li, X; Lu, H; Tan, R; Wang, F; Wang, J; Wu, G; Zhao, X | 1 |
DiPetrillo, L; Ehrich, E; Kelsh, D; Nangia, N; Pathak, S; Puhl, MD; Setnik, B; Stanford, AD; Sun, L; Vince, B | 1 |
Beeker, A; Berkhof, J; Neefjes, ECW; Rhodius, CA; Ten Oever, D; van den Berg, HP; van der Vliet, HJ; van der Vorst, MJDL; van der Wijngaart, H; Verheul, HMW | 1 |
Law, PY; Loh, HH; Tao, PL; Wang, Y; Yang, PP; Yeh, TK | 1 |
Ishikawa, H; Sato, J; Shino, M; Suzuki, T; Tanaka, R | 1 |
Banks, ML; Blake, S; Bremer, PT; Hwang, CS; Janda, KD; Poklis, JL; Tenney, RD; Zhou, B | 1 |
Bass, A; Pixton, GC; Rauck, RL; Wilson, JG; Wolfram, G | 1 |
Ashizawa, K; Hara, T; Ikeda, T; Ishii, K; Kamada, M; Komatsu, Y; Matsuo, K; Morishita, S; Ryu, E; Yamaguchi, M; Yamashita, H | 1 |
Hu, C; Luo, Z; Miao, J; Shen, Y; Shu, S; Wang, Y; Zhu, X | 1 |
Bergman, J; Doyle, RJ; Kangas, BD; Porter, EN; Withey, SL | 1 |
Freeman, KB; Huskinson, SL; Naylor, JE; Prisinzano, TE; Townsend, EA; Zamarripa, CA | 1 |
Accetturo, C; Pravetoni, M; Raleigh, MD | 1 |
Akbarali, HI; Beardsley, PM; Komla, E; Moisa, LT; Mustafa, MA; Poklis, JL; Walentiny, DM | 1 |
Azar, MR; Cunningham, JI; Dean, RL; Deaver, DR; Eyerman, DJ; Koob, GF; Todtenkopf, MS | 1 |
Daunert, S; Deo, S; Dikici, E; Peyravian, N; Sun, E; Toborek, M | 1 |
Antonijoan, RM; Cardona, G; Ferreri, L; Mas-Herrero, E; Pla-Juncà, F; Riba, J; Rodriguez-Fornells, A; Valle, M; Zatorre, RJ | 1 |
Allen, MI; Banks, ML; Cornelissen, JC; Nader, MA; Newman, AH; Woodlief, K | 1 |
10 review(s) available for naltrexone and oxycodone
Article | Year |
---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic | 2000 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.
Topics: Animals; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Naltrexone; Oxycodone | 2007 |
Opioid formulations designed to resist/deter abuse.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Drug Combinations; Humans; Morphine; Naltrexone; Niacin; Opioid-Related Disorders; Oxycodone; Pain; United States | 2010 |
The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review.
Topics: Analgesics, Opioid; Clinical Trials as Topic; Constipation; Delayed-Action Preparations; Drug Combinations; Humans; Laxatives; Naloxone; Naltrexone; Narcotic Antagonists; Oxycodone; Quaternary Ammonium Compounds | 2010 |
[Opiate induced constipation--mechanisms, relevance and treatment].
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Constipation; Drug Therapy, Combination; Gastrointestinal Motility; Humans; Laxatives; Naltrexone; Narcotic Antagonists; Oxycodone; Quaternary Ammonium Compounds | 2013 |
Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?
Topics: Analgesics, Opioid; Delayed-Action Preparations; Humans; Illicit Drugs; Morphine; Naltrexone; Opioid-Related Disorders; Oxycodone | 2014 |
Pharmacokinetic and pharmacodynamic evaluation of oxycodone and naltrexone for the treatment of chronic lower back pain.
Topics: Analgesics, Opioid; Animals; Chronic Pain; Delayed-Action Preparations; Drug Combinations; Humans; Low Back Pain; Naltrexone; Opioid-Related Disorders; Oxycodone; Practice Guidelines as Topic | 2016 |
Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Topics: Constipation; Defecation; Female; Gastrointestinal Agents; Humans; Intestinal Diseases; Male; Nalbuphine; Naloxone; Naltrexone; Narcotic Antagonists; Neoplasms; Opioid-Related Disorders; Oxycodone; Palliative Care; Piperidines; Quaternary Ammonium Compounds; Randomized Controlled Trials as Topic; Receptors, Opioid, mu | 2018 |
Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.
Topics: Adult; Analgesics, Opioid; Child; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Neoplasms; Opioid-Induced Constipation; Oxycodone; Palliative Care; Quaternary Ammonium Compounds; Substance Withdrawal Syndrome | 2022 |
14 trial(s) available for naltrexone and oxycodone
Article | Year |
---|---|
A clinical laboratory model for direct assessment of medication-induced antihyperalgesia and subjective effects: initial validation study.
Topics: Adult; Affect; Analgesics; Analgesics, Opioid; Double-Blind Method; Emotions; Female; Hot Temperature; Humans; Hyperalgesia; Male; Models, Psychological; Naltrexone; Narcotic Antagonists; Oxycodone; Pain Measurement; Pupil; Reproducibility of Results; Research Design; Ultraviolet Rays | 2000 |
Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.
Topics: Adolescent; Adult; Aged; Analgesia; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Osteoarthritis; Oxycodone; Pain; Pain Measurement; Patient Satisfaction; Treatment Outcome | 2005 |
Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain.
Topics: Adolescent; Adult; Aged; Analgesics; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Low Back Pain; Male; Middle Aged; Naltrexone; Oxycodone; Pain Measurement; Substance Withdrawal Syndrome; Treatment Outcome | 2006 |
Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.
Topics: Adolescent; Adult; Aged; Analgesics, Opioid; Behavior, Addictive; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Oxycodone; Placebos | 2010 |
Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a sing
Topics: Adolescent; Adult; Analgesics, Opioid; Area Under Curve; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Oxycodone; Tablets; Therapeutic Equivalency; Young Adult | 2012 |
Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
Topics: Adult; Analgesics, Opioid; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Drug Interactions; Ethanol; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Oxycodone; Young Adult | 2015 |
A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Analysis of Variance; Chronic Pain; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Humans; Low Back Pain; Middle Aged; Naltrexone; Narcotic Antagonists; Oxycodone; Pain Measurement; Treatment Outcome; Young Adult | 2015 |
Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): A randomized, controlled abuse-potential study in nondependent recreational opioid users.
Topics: Administration, Intranasal; Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Users; Female; Humans; Male; Middle Aged; Naltrexone; Oxycodone; Patient Satisfaction; Young Adult | 2015 |
Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
Topics: Administration, Oral; Adolescent; Adult; Analgesics, Opioid; Area Under Curve; Biotransformation; Capsules; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Drug Compounding; Fasting; Female; Food-Drug Interactions; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Naltrexone; Narcotic Antagonists; Oxycodone; Postprandial Period; Young Adult | 2015 |
Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.
Topics: Adolescent; Adult; Cross-Over Studies; Delayed-Action Preparations; Discrimination, Psychological; Double-Blind Method; Drug Combinations; Drug Users; Female; Humans; Male; Middle Aged; Naltrexone; Oxycodone; Reinforcement, Psychology; Substance Abuse, Intravenous; Young Adult | 2016 |
Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain.
Topics: Adult; Analgesics, Opioid; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Efficiency; Female; Humans; Low Back Pain; Male; Middle Aged; Naltrexone; Oxycodone; Pain Measurement; Patient Reported Outcome Measures; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Visual Analog Scale | 2017 |
Life satisfaction and pain interference in spine surgery patients before and after surgery: comparison between on-opioid and opioid-naïve patients.
Topics: Acetaminophen; Adult; Aged; Analgesics, Opioid; Drug Combinations; Elective Surgical Procedures; Female; Humans; Ketoprofen; Male; Meloxicam; Middle Aged; Naltrexone; Oxycodone; Pain; Pain Measurement; Personal Satisfaction; Prospective Studies; Quality of Life; Spine; Surveys and Questionnaires; Tromethamine; Young Adult | 2018 |
Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain.
Topics: Adult; Analgesics, Opioid; Chronic Pain; Cross-Over Studies; Delayed-Action Preparations; Fasting; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Oxycodone; Tablets; Therapeutic Equivalency | 2020 |
The role of opioid transmission in music-induced pleasure.
Topics: Analgesics, Opioid; Music; Naltrexone; Oxycodone; Pleasure; Reward | 2023 |
40 other study(ies) available for naltrexone and oxycodone
Article | Year |
---|---|
Analgesic narcotic antagonists. 8. 7 alpha-Alkyl-4,5 alpha-epoxymorphinan-6-ones.
Topics: Analgesics; Animals; Chemical Phenomena; Chemistry; Codeine; Hydrocodone; In Vitro Techniques; Mice; Narcotic Antagonists; Rats; Reaction Time | 1981 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1.
Topics: Analgesics, Opioid; HEK293 Cells; Humans; Inhibitory Concentration 50; Models, Molecular; Organic Cation Transporter 1; Permeability; Protein Conformation | 2019 |
Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study.
Topics: Animals; Cell Division; Codeine; Hydromorphone; Immune System; Immunosuppression Therapy; Interleukin-2; Male; Mice; Morphine; Nalorphine; Naloxone; Naltrexone; Narcotics; Oxycodone; Structure-Activity Relationship | 1997 |
Affinity profiles of novel delta-receptor selective benzofuran derivatives of non-peptide opioids.
Topics: Animals; Benzeneacetamides; Benzofurans; Binding, Competitive; Brain; Cell Membrane; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalin, D-Penicillamine (2,5)-; Enkephalins; Naloxone; Naltrexone; Oligopeptides; Oxycodone; Oxymorphone; Pyrrolidines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Opioid, delta; Receptors, Opioid, mu; Tritium | 1998 |
Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol.
Topics: Adult; Aged; Analgesics, Opioid; Benzodiazepines; Chromatography, High Pressure Liquid; Corticosterone; Cytosol; Dihydrotestosterone; Enzyme Inhibitors; Humans; Kinetics; Liver; Microsomes, Liver; Middle Aged; Naloxone; Naltrexone; Oxidoreductases; Oxycodone; Reproducibility of Results; Substrate Specificity; Testosterone; Vitamin K | 2000 |
Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats.
Topics: Animals; Avoidance Learning; Conditioning, Classical; Dose-Response Relationship, Drug; Female; Injections, Subcutaneous; Morphine Dependence; Motivation; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Orientation; Oxycodone; Rats; Rats, Sprague-Dawley; Reward; Substance Withdrawal Syndrome | 2005 |
Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats.
Topics: Animals; Avoidance Learning; Conditioning, Operant; Cues; Electroshock; Extinction, Psychological; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Narcotics; Oxycodone; Rats; Rats, Sprague-Dawley; Recurrence; Reinforcement Schedule; Reward; Self Administration | 2005 |
Antinociceptive effect of oxycodone in diabetic mice.
Topics: Analgesics, Opioid; Animals; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred ICR; Morphine; Naltrexone; Narcotic Antagonists; Oxycodone; Pain; Pain Measurement; Time Factors | 2005 |
Characterization of the antinociceptive effects of oxycodone in diabetic mice.
Topics: Analgesics, Opioid; Animals; Area Under Curve; Diabetes Mellitus, Experimental; Injections, Intraventricular; Injections, Spinal; Injections, Subcutaneous; Mice; Mice, Inbred ICR; Naltrexone; Narcotic Antagonists; Oxycodone; Pain; Pain Measurement; Streptozocin | 2006 |
Involvement of mu1-opioid receptor on oxycodone-induced antinociception in diabetic mice.
Topics: Analgesics, Opioid; Animals; Diabetes Mellitus, Experimental; Male; Mice; Mice, Inbred ICR; Naloxone; Naltrexone; Oxycodone; Receptors, Opioid, mu; Streptozocin | 2007 |
Oxycodone's mechanism of action and potency differences after spinal and systemic routes of administration.
Topics: Analgesics, Opioid; Animals; Injections, Intravenous; Injections, Spinal; Naltrexone; Oxycodone; Rats | 2007 |
Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hyperalgesia; Injections, Spinal; Male; Naltrexone; Narcotic Antagonists; Neuralgia; Oxycodone; Pain Threshold; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Receptors, Opioid, mu; Signal Transduction; Spinal Nerves | 2008 |
Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.
Topics: Adolescent; Analgesics, Opioid; Delayed-Action Preparations; Female; Heroin Dependence; Humans; Metabolic Clearance Rate; Naltrexone; Narcotic Antagonists; Oxycodone; Patient Acceptance of Health Care; Substance Withdrawal Syndrome | 2008 |
FDA panel debates merits of next-generation opioid formulations.
Topics: Analgesics, Opioid; Delayed-Action Preparations; Drug Approval; Humans; Morphine; Naltrexone; Oxycodone; United States; United States Food and Drug Administration | 2009 |
Emerging new therapeutic options for the management of opioid induced constipation.
Topics: Alprostadil; Analgesics, Opioid; Constipation; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Laxatives; Lubiprostone; Naloxone; Naltrexone; Narcotic Antagonists; Oxycodone; Quaternary Ammonium Compounds | 2010 |
Investigation of structure, vibrational and NMR spectra of oxycodone and naltrexone: a combined experimental and theoretical study.
Topics: Crystallography, X-Ray; Magnetic Resonance Spectroscopy; Models, Molecular; Naltrexone; Narcotic Antagonists; Oxycodone; Quantum Theory; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman | 2011 |
The implications of tamper-resistant formulations for opioid rotation.
Topics: Analgesics, Opioid; Chronic Pain; Delayed-Action Preparations; Drug Combinations; Drug Compounding; Drug Tolerance; Humans; Morphine; Naltrexone; Opioid-Related Disorders; Oxycodone; Oxymorphone; Patient Selection | 2012 |
Technology: Barriers to misuse.
Topics: Analgesics, Opioid; Chemistry, Pharmaceutical; Drug Combinations; Drug Overdose; Drug Users; Humans; Morphine; Naltrexone; Opioid-Related Disorders; Oxycodone; Prodrugs | 2015 |
[Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Alcoholism; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Pharmacovigilance; Substance Withdrawal Syndrome | 2015 |
Corrections.
Topics: Arthritis; Capsules; Drug Combinations; Etanercept; Humans; Injections; Isoquinolines; Naltrexone; Nausea; Oxycodone; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Tumor Necrosis Factor-alpha; Vomiting | 2016 |
Choice between delayed food and immediate oxycodone in rats.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Behavior, Animal; Choice Behavior; Delay Discounting; Disease Models, Animal; Eating; Feeding Behavior; Humans; Male; Naltrexone; Oxycodone; Rats; Reward; Time Factors | 2016 |
Choice between delayed food and immediate opioids in rats: treatment effects and individual differences.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Choice Behavior; Conditioning, Operant; Delay Discounting; Dose-Response Relationship, Drug; Feeding Behavior; Individuality; Injections, Intravenous; Male; Naltrexone; Oxycodone; Piperidines; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Remifentanil; Reward; Self Administration; Time Factors | 2017 |
Role of mu, but not delta or kappa, opioid receptors in context-induced reinstatement of oxycodone seeking.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Conditioning, Operant; Male; Naltrexone; Narcotic Antagonists; Oxycodone; Rats, Sprague-Dawley; Receptors, Opioid; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2019 |
Methylnaltrexone-Associated Bowel Perforation in Postoperative Opioid-Induced Constipation and Ogilvie Syndrome: A Case Report.
Topics: Analgesics, Opioid; Colonic Pseudo-Obstruction; Constipation; Decompression, Surgical; Humans; Hydromorphone; Intestinal Perforation; Low Back Pain; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Postoperative Complications; Quaternary Ammonium Compounds; Spinal Stenosis | 2019 |
Short term exposure to oxycodone alters the survival, proliferation and differentiation of rat embryonic neural stem cell in vitro.
Topics: Analgesics, Opioid; Animals; Apoptosis; Cell Differentiation; Cell Proliferation; Cell Survival; Embryonic Stem Cells; Female; Morphine; Naltrexone; Neural Stem Cells; Oxycodone; Pregnancy; Rats; Rats, Sprague-Dawley | 2018 |
Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
Topics: Adult; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Pentazocine; Placebos | 2019 |
Optimal treatment of opioid induced constipation in daily clinical practice - an observational study.
Topics: Aged; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Laxatives; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neoplasms; Oxycodone; Pain Management; Prospective Studies; Quaternary Ammonium Compounds; Retrospective Studies; Surveys and Questionnaires | 2019 |
Delta-opioid receptor antagonist naltrindole reduces oxycodone addiction and constipation in mice.
Topics: Analgesics; Animals; Constipation; Drug Tolerance; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Receptors, Opioid, delta; Respiratory Insufficiency | 2019 |
A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting.
Topics: Aged; Analgesics, Opioid; Antiemetics; Constipation; Female; Humans; Incidence; Male; Middle Aged; Morphine; Naltrexone; Narcotic Antagonists; Nausea; Oxycodone; Receptors, Opioid; Retrospective Studies; Vomiting | 2020 |
Vaccine blunts fentanyl potency in male rhesus monkeys.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Conditioning, Operant; Dose-Response Relationship, Drug; Fentanyl; Macaca mulatta; Male; Naltrexone; Narcotic Antagonists; Nociception; Oxycodone; Receptors, Opioid, mu; Tetanus Toxoid; Vaccines; Vaccines, Conjugate | 2019 |
Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Pain; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Low Back Pain; Male; Middle Aged; Naltrexone; Oxycodone; Randomized Controlled Trials as Topic; Young Adult | 2020 |
Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis.
Topics: Analgesics, Opioid; Breast Neoplasms; Cancer Pain; Female; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Induced Constipation; Oxycodone; Substance Withdrawal Syndrome | 2020 |
Discrimination learning in oxycodone-treated nonhuman primates.
Topics: Analgesics, Opioid; Animals; Discrimination Learning; Dose-Response Relationship, Drug; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Primates; Saimiri; Self Administration; Substance Withdrawal Syndrome | 2020 |
Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.
Topics: Analgesics, Opioid; Animals; Behavior, Addictive; Cocaine; Diterpenes, Clerodane; Dose-Response Relationship, Drug; Macaca mulatta; Male; Morphinans; Naltrexone; Narcotic Antagonists; Oxycodone; Receptors, Opioid, kappa; Reinforcement, Psychology; Self Administration; Spiro Compounds | 2020 |
Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity.
Topics: Analgesics, Opioid; Animals; Brain; Delayed-Action Preparations; Hemocyanins; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Rats; Vaccines | 2020 |
Methylnaltrexone crosses the blood-brain barrier and attenuates centrally-mediated behavioral effects of morphine and oxycodone in mice.
Topics: Analgesics, Opioid; Animals; Blood-Brain Barrier; Dose-Response Relationship, Drug; Male; Mice; Mice, Inbred C57BL; Morphine; Naltrexone; Narcotic Antagonists; Oxycodone; Pain Measurement; Quaternary Ammonium Compounds | 2021 |
Samidorphan, an opioid receptor antagonist, attenuates drug-induced increases in extracellular dopamine concentrations and drug self-administration in male Wistar rats.
Topics: Amphetamine; Animals; Cocaine; Dopamine; Ethanol; Humans; Male; Microdialysis; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Oxycodone; Rats; Rats, Wistar; Receptors, Opioid; Receptors, Opioid, mu; Self Administration; Substance-Related Disorders | 2021 |
Opioid Antagonist Nanodrugs Successfully Attenuate the Severity of Ischemic Stroke.
Topics: Analgesics, Opioid; Animals; Ischemic Stroke; Mice; Morphine; Naloxone; Naltrexone; Nanoparticles; Narcotic Antagonists; Opioid-Related Disorders; Oxycodone; Stroke; Tight Junction Proteins | 2022 |
Effects of selective dopamine D3 receptor partial agonist/antagonists on oxycodone self-administration and antinociception in monkeys.
Topics: Analgesics, Opioid; Animals; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Macaca fascicularis; Male; Naltrexone; Opioid-Related Disorders; Oxycodone; Receptors, Dopamine D3; Self Administration | 2023 |